Considers the decision to go public. BioTransplant is an early stage biotechnology company that has to decide how to fund its research and development. Pros and cons of the public offer are analyzed in comparison with alternative sources of funding. "Hide
by Paul A. Gompers, Alexander Tsai Source: Harvard Business School 30 pages. Publication Date: March 24, 1997. Prod. #: 297095-PDF-ENG
Related Case Solutions & Analyses:
Green Mountain Coffee Roasters, Inc.
Google Glass
A Tale of Storytelling: Its Allure and its Traps
Clef Company: Turnover
Health Care Access for All: Making the Dream a Reality
JOG Sports: Sports Apparel and Ice Hockey in Thailand
Brookstone Ob-Gyn Associates
FC Barcelona: The Cesc Febregas Saga
Suntech Power Holdings (B): The Post-IPO Years
Freemark Abbey Winery
